Abstract
ObjectiveSpinal muscular atrophy (SMA) is a neuromuscular disorder that manifests with motor deterioration and respiratory complications. The paradigm of care is shifting as disease-modifying therapies including nusinersen, onasemnogene abeparvovec and...
Paper version not known (Free)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have